106
Participants
Start Date
November 15, 2019
Primary Completion Date
June 14, 2022
Study Completion Date
June 14, 2022
ADX-2191 (intravitreal methotrexate 0.8%)
ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
Standard surgical care procedure
Standard surgical care performed upon completion of pars plana vitrectomy
Long Island VitreoRetinal Consultants, Forest Hills
Mid Atlantic Retina, Philadelphia
Duke Health Center, Durham
Emory Eye Center, Atlanta
Florida Retina Institute, Orlando
Bascom Palmer Eye Institute, Palm Beach Gardens
Associated Retinal Consultants, Royal Oak
Kresge Eye Institute, Detroit
University of Iowa, Iowa City
Vitreo-Retinal Surgery, Minneapolis
Mayo Clinic Ophthalmology, Rochester
Illinois Retina Associates, Joliet
University of Illinois at Chicago, Chicago
The Retina Institute, St Louis
Retina Consultants of Houston, Houston
Retinal Consultants of Arizona, Phoenix
University of California Los Angeles, Los Angeles
OHSU Casey Eye Institute, Portland
University of Washington, Seattle
Tufts Medical Center, Boston
Ophthalmic Consultants of Boston, Boston
Massachusetts Eye and Ear, Boston
New England Retina Consultants, Springfield
Lead Sponsor
Aldeyra Therapeutics, Inc.
INDUSTRY